Alkermes Plc (ALKS)vsAstraZeneca PLC (AZN)
ALKS
Alkermes Plc
$33.71
-1.26%
HEALTHCARE · Cap: $5.62B
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3880% more annual revenue ($58.74B vs $1.48B). AZN leads profitability with a 17.4% profit margin vs 16.4%. AZN appears more attractively valued with a PEG of 1.54. AZN earns a higher WallStSmart Score of 64/100 (C+).
ALKS
Buy50
out of 100
Grade: C-
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.1%
Fair Value
$76.10
Current Price
$33.71
$42.39 discount
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
Revenue declined 10.6%
Earnings declined 67.0%
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Debt/Equity. Profitability is solid with margins at 16.4% and operating margin at 15.1%.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, Revenue Growth, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
ALKS profiles as a declining stock while AZN is a value play — different risk/reward profiles.
ALKS carries more volatility with a beta of 0.39 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 50/100), backed by strong 17.4% margins. ALKS offers better value entry with a 54.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?